LogicBio Therapeutics (LogicBio Therapeutics) Accumulated Depreciation : $0.00 Mil (As of Jun. 2022)

View and export this data going back to 2018. Start your Free Trial

What is LogicBio Therapeutics Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

LogicBio Therapeutics's quarterly accumulated depreciation declined from Dec. 2021 ($-1.39 Mil) to Mar. 2022 ($0.00 Mil) but then stayed the same from Mar. 2022 ($0.00 Mil) to Jun. 2022 ($0.00 Mil).

LogicBio Therapeutics's annual accumulated depreciation increased from Dec. 2019 ($-0.34 Mil) to Dec. 2020 ($-0.81 Mil) and increased from Dec. 2020 ($-0.81 Mil) to Dec. 2021 ($-1.39 Mil).

LogicBio Therapeutics Accumulated Depreciation Historical Data

The historical data trend for LogicBio Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LogicBio Therapeutics Accumulated Depreciation Chart

LogicBio Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Accumulated Depreciation

Get a 7-Day Free Trial

-0.06

-0.05

-0.34

-0.81

-1.39

LogicBio Therapeutics Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Accumulated Depreciation	Get a 7-Day Free Trial															-	-	-1.39	-	-

LogicBio Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

LogicBio Therapeutics Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of LogicBio Therapeutics's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

LogicBio Therapeutics (LogicBio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LogicBio Therapeutics Inc (NAS:LOGC) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Hayden Avenue, 2nd Floor, Lexington, MA, USA, 02421

Website

https://www.logicbio.com

LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301.

Executives

Mark J Enyedy	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Mariana Nacht	officer: Chief Scientific Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Daniel Gruskin	officer: Chief Medical Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Susan Kahn	director	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Joshua Blacher	officer: Interim CFO	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Andrea Paul	officer: General Counsel and Secretary	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Frederic Chereau	director, officer: See Remarks	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Kyle Chiang	officer: Chief Operating Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Cecilia Jones	officer: Chief Financial Officer	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jonathan Quick	officer: Senior Director-Finance	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jeff Goater	director	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Erez Chimovits	director	P.O. BOX 4023, HERZLIYA PITUACH L3 4614001
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022